Save
esh.org
Case-based lecture: Interferon alpha
ESH eLearning, Andreas Buchert, 348314
Case-based lecture: New technologies in monitoring
ESH eLearning, Nick CROSS, 348313
Interactive case: Prognostic factors for successful TFR
ESH eLearning, Susanne Saussele, 348312
Panel discussion
ESH eLearning, Faculty / Presenters, 348311
Brief oral Communication: Cpi-0610, a bromodomain and extraterminal domain protein (BET) inhibitor, in combination with ruxolitinib, in JAK-Inhibitor-Naïve Myelofibrosis patients: update of manifest Phase 2 study
ESH eLearning, Francesco Passamonti, 348310
Interactive case: Venetoclax data
ESH eLearning, Srdan Verstovsek, 348309
Interactive case: CMML
ESH eLearning, Donal McLornan, 348308
Case-based lecture: Blast crisis in CML
ESH eLearning, Dragana Milojkovic, 348307
Case-based lecture: Management of rare translocations MPN entities FGFR1 and JAK2 partner geners
ESH eLearning, Andreas Reiter, 348305
Panel discussion
ESH eLearning, Faculty / Presenters, 348304
Brief oral Communication: Genomic analysis of primary and secondary Myelofibrosis redefines the prognostic impact of ASXL1 mutations: a FIM study
ESH eLearning, Damien Luque Paz, 348303
Interactive case: When to switch from Ruxolitinib
ESH eLearning, Haifa Kathrin Al-Ali, 348302
Case-based lecture: Evolving therapies for myelofibrosis; non-JAK inhibitor approaches
ESH eLearning, John Mascarenhas, 348301
Case-based lecture: JAK inhibitors in combination
ESH eLearning, Srdan Verstovsek, 348300
Case-based lecture: Other JAK inhibitors (Momelotinib, Pacritinib)
ESH eLearning, Adam Mead, 348299
Interactive case: Therapy of Myelofibrosis with approved agents
ESH eLearning, Ruben Mesa, 348298
Discussion
ESH eLearning, Faculty / Presenters, 348297
No
ESH eLearning, Delphine Rea, 348296
Yes
ESH eLearning, Jane APPERLEY, 348295
Introduction
ESH eLearning, Andreas Hochhaus, 348294
Discussion
ESH eLearning, Faculty / Presenters, 348293
Interferon alpha in pregnancies of Myeloproliferative Neoplasms
ESH eLearning, Martin Griesshammer, 348292
Russian recommendations to manage pregnancy in CML
ESH eLearning, Ekaterina Chelysheva, 348291
Pregnancy and TKI
ESH eLearning, Elisabetta Abruzzese, 348290
Introduction
ESH eLearning, Jane APPERLEY, 348289
Discussion
ESH eLearning, Faculty / Presenters, 348288
Infections in MPN - patients survey
ESH eLearning, Florian Heidel, 348287
COVID-19 and CML
ESH eLearning, Delphine Rea, 348286
Introduction
ESH eLearning, Ruben Mesa, 348285
Discussion
ESH eLearning, Faculty / Presenters, 348284
No
ESH eLearning, Claire Harrison, 348283
Yes
ESH eLearning, Florian Heidel, 348282
Introduction
ESH eLearning, Ruben Mesa, 348281
Panel discussion
ESH eLearning, Faculty / Presenters, 348280
Case-based lecture: Vascular risk assessment in MPN
ESH eLearning, Emmanuel Messas, 348279
Case-based lecture: Pre-Myelofibrosis & Myelofibrosis
ESH eLearning, Paola Guglielmelli, 348278
Case-based lecture : Polycythemia Vera
ESH eLearning, Naseema Gangat, 348277
Case-based Lecture: Essential Thrombocythemia
ESH eLearning, Alberto Alvarez, 348276
Interactive case: MPN risk stratification
ESH eLearning, Francesco Passamonti, 348275
Panel discussion
ESH eLearning, Faculty / Presenters, 348274
Interactive CML case: Double trouble
ESH eLearning, Peter Westerweel, 348273
Case-based lecture: Salvage treatment and other lines
ESH eLearning, Gianantonio Rosti, 348272
Case-based lecture: The use of imatinib generics in the CML therapy
ESH eLearning, Tomasz Sacha, 348271
Case-based lecture: First line TKIs
ESH eLearning, Giuseppe Saglio, 348270
Interactive case
ESH eLearning, Francois-Xavier Mahon, 348269
Panel discussion
ESH eLearning, Faculty / Presenters, 348268
Brief oral Communication: Addition of Parsaclisib (INCB050465), a PI3Kδ inhibitor, in patients with suboptimal response to ruxolitinib: a phase 2 study in patients with Myelofibrosis
ESH eLearning, Abdulraheem Yacoub, 348267
Interactive case: Hepcidin Agonists in Polycythemia Vera
ESH eLearning, Marina Kremyanskaya, 348266
Case-based lecture: use of ruxolitinib in essential Thrombocythemia and Splanchnic vessel thrombosis
ESH eLearning, Brady L. Stein, 348265
Case-based lecture: Hydroxyurea / Resistance to Hydroxyurea
ESH eLearning, Allessandro M. Vannucchi, 348263
Interactive case
ESH eLearning, Jean-Jacques Kiladjian, 348262
Panel Discussion
ESH eLearning, Faculty / Presenters, 348261
MDS/CMML with TET2 or IDH mutations are associated with Systemic Inflammatory and Autoimmune Diseases and T-cell dysregulation
ESH eLearning, Lin-Pierre Zhao, 348260
Panel Discussion
ESH eLearning, Faculty / Presenters, 348259
How to target CHIP?
ESH eLearning, Klaus Metzeler, 348258
Current MDS/CMML clinical trials in Europe
ESH eLearning, Valeria Santini, 348255
Panel Discussion
ESH eLearning, Faculty / Presenters, 348254
Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase Ib Study
ESH eLearning, Andrew Brunner, 348253
Novel strategies to treat cytopenia in Low Risk MDS
ESH eLearning, Uwe Platzbecker, 348252
Management of HMA failure
ESH eLearning, Valeria Santini, 348251
Strategies to improve HMA based therapy
ESH eLearning, Pierre Fenaux, 348250
Higher risk MDS: Lessons from elderly AML A renewed role for intensive chemotherapy (CPX 351…)?
ESH eLearning, Lionel Adès, 348249
Panel Discussion
ESH eLearning, Faculty / Presenters, 348248
Current treatment guidelines for CMML and rare subtypes
ESH eLearning, Raphael Itzykson, 348247
HMAs: When and how
ESH eLearning, Mikkael Sekeres, 348246
ESA and other growth factors
ESH eLearning, Valeria Santini, 348245
Overview of MDS treatment
ESH eLearning, Eva Hellström- Lindberg, 348244
Specific Subtypes of MDS, based on Morphology and Molecular Biology
ESH eLearning, Faculty / Presenters, 348243
Specific Subtypes of MDS, based on Morphology and Molecular Biology
ESH eLearning, Klaus Geissler, 348242
Specific Subtypes of MDS, based on Morphology and Molecular Biology
ESH eLearning, Aristoteles Giagounidis, 348241
Specific Subtypes of MDS, based on Morphology and Molecular Biology
ESH eLearning, Eric Solary, 348240
Panel Discussion
ESH eLearning, Faculty / Presenters, 348239
DEBATE: IS NGS useful in MDS? - No
ESH eLearning, Guillermo Sanz, 348238
Roundtable: Response criteria (with recent proposed changes, IWG 2018)
ESH eLearning, Pierre Fenaux, 348237
Role of comorbidities and quality of life in prognosis. New evaluation scales (QUALMS…)
ESH eLearning, Reinhard Stauder, 348236
Examining prognostic indicators in MDS
ESH eLearning, Michael Pfeilstöcker, 348235
Controversial debate: Genetics versus epigenetics in myeloid disease - Chair
ESH eLearning, Uwe Platzbecker, 348232
Panel Discussion
ESH eLearning, Faculty / Presenters, 348231
Immunological mess in MDS; is there a target?
ESH eLearning, Shahram Kordasti, 348230
Bone biology and the osteo-hematopoietic niche
ESH eLearning, Ulrike Baschant, 348229
Panel Discussion
ESH eLearning, Faculty / Presenters, 348228
Druggable molecular targets in MDS and elderly AML) (IDH, TP53…)
ESH eLearning, Torsten Haferlach, 348227
Multiple acquired clonal steps to MDS, molecular architecture and its progression to AML
ESH eLearning, Oliver Kosmider, 348226
Panel Discussion
ESH eLearning, Faculty / Presenters, 348225
Relationships between inherited and acquired predisposition
ESH eLearning, Jaroslaw Maciejewski, 348224
Therapy related MDS and other environmental factors in MDS
ESH eLearning, Maria Teresa Voso, 348223
General discussion
ESH eLearning, Faculty / Presenters, 347827
Time limited vs continuous treatments
ESH eLearning, Barbara Eichhorst, 347826
Sequential vs combination treatments
ESH eLearning, William Wierda, 347825
MRD as a dynamic endpoint
ESH eLearning, Peter Hillmen, 347824
General discussion
ESH eLearning, Faculty / Presenters, 347823
Venetoclax
ESH eLearning, J.F. Seymour, 347821
PI3K
ESH eLearning, Jennifer Brown, 347820
Clonal evolution
ESH eLearning, Davide Rossi, 347819
General discussion
ESH eLearning, Faculty / Presenters, 347818
Gastroenterology
ESH eLearning, Stefano Fagiuoli, 347817
Infectious diseases
ESH eLearning, Michele Bartoletti, 347816
Dermatologist
ESH eLearning, Nicole Le, 347815
Cardiologist
ESH eLearning, Javid Moslehi, 347814
General discussion
ESH eLearning, Faculty / Presenters, 347813

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.


Save Settings